Sign In
Buy ALKS
$42.76
+1.44 (+3.48%)
At Close: Jun 03, 2026
Alkermes to Report Second Quarter 2021 Financial Results on July 28, 2021
04:00pm, Wednesday, 21'st Jul 2021
DUBLIN, July 21, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m.
7 Growth Stocks to Buy As Meme Stock Mania Fades
05:06pm, Monday, 19'th Jul 2021
As the craze for meme stocks fades away, investors should consider growth investing to generate big returns. Here are 7 growth stocks to buy today.
Forget Biogen: These 2 Under-the-Radar Biotechs Are Also Celebrating Breakthroughs
05:28am, Sunday, 13'th Jun 2021
Biogen isn't the only company whose shares should benefit from a breakthrough drug.
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
09:15am, Friday, 04'th Jun 2021
DUBLIN, June 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced new data from its ARTISTRY clinical development program for nemvaleukin alfa (nemvaleukin), Alkermes' novel, investig
Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference
06:38pm, Thursday, 03'rd Jun 2021
DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conferen
Alkermes' (ALKS) Schizophrenia, Bipolar I Disorder Drug Approved
09:47am, Wednesday, 02'nd Jun 2021
The FDA approves Alkermes' (ALKS) Lybalvi for the treatment of adults with schizophrenia or bipolar I disorder. Shares up
Alkermes Shares Move Higher On FDA Approval Of Schizophrenia, Bipolar Med
09:35am, Tuesday, 01'st Jun 2021
The FDA has approved Alkermes plc's (NASDAQ: ALKS) Lybalvi, a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, and samidorphan, a new chemical ent
Alkermes Announces FDA Approval of LYBALVI™ for the Treatment of Schizophrenia and Bipolar I Disorder
07:00am, Tuesday, 01'st Jun 2021
DUBLIN, June 1, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has approved LYBALVI™ (olanzapine and samidorphan) for the treatme
DUBLIN, May 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will host a webcast and conference call at 4:00 p.m. ET (9:00 p.m.
DUBLIN, May 13, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the company will begin accepting applications for its Alkermes Inspiration Grants® program beginning on May 20,
Why Shares of Alkermes Rose 18% Last Month
04:11pm, Friday, 07'th May 2021
An agreement with an activist investor capped a busy month.
Want to Make Money in Biotech? Do This First
06:17am, Friday, 07'th May 2021
Keeping track of upcoming events is important.
Alkermes to Take Part in the BofA Securities 2021 Virtual Healthcare Conference
04:00pm, Wednesday, 05'th May 2021
DUBLIN, May 5, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the BofA Securities 2021 Healthcare Conference on Wednesd
Alkermes' (ALKS) Q1 Earnings Rise Y/Y, Revenues Beat Estimates
12:02pm, Thursday, 29'th Apr 2021
Alkermes' (ALKS) earnings rise year over year in the first quarter of 2021. Revenues surpass estimates.
Alkermes Plc (ALKS) CEO Richard Pops on Q1 2021 Results - Earnings Call Transcript
02:25pm, Wednesday, 28'th Apr 2021
Alkermes Plc (ALKS) CEO Richard Pops on Q1 2021 Results - Earnings Call Transcript
